Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia

埃塞俄比亚西北部巴赫达尔市接受抗逆转录病毒治疗的成年HIV感染者出现药物不良反应的时间及其相关因素

阅读:1

Abstract

BACKGROUND: Adverse drug reactions (ADRs) are harmful and unintended reactions to medicines given at standard doses. Although the antiretroviral treatment (ART) changed the global HIV epidemic significantly, it's associated adverse events is huge. Therefore, investigating the rate and development of ADRs of ART provides vital information for monitoring risks. METHODS: Retrospective study was conducted among patients on ART from July1/2011-June 30/2016 at Felege Hiwot referral hospital. Data were collected using checklist and document review. The p-value and hazard ratio with its confidence interval was used to show presence and strength of association. RESULTS: A total of 602 subjects were studied. The rate of occurrence of major ADRs was 4.3/100PY. Patients with no formal and completed primary education were at higher risk of developing ADRs compared to those with higher level education [AHR = 8, 95% CI: 2.53-25.20, AHR = 4.9, 95% CI: 1.65-14.44]. The risks of ADRs among patients working in NGOs were more than four times compared to those in governmental organizations [AHR = 4.3, 95% CI: 1.42-13.31]. The risks of ADRs in WHO clinical stage II, III and IV were much higher than in stage I [AHR = 4, 95% CI: 1.33-11.93, AHR = 5.3, 95% CI: 2.02-13.79 and AHR = 7, 95% CI: 2.51-20.10] respectively. Moreover, patients didn't receive OI prophylaxis were more three times at risk of ADRs compared to those received [AHR = 3.2, 95% CI: 1.47-7.08]. CONCLUSIONS: Most of the ADRs cases were occurred within a year after initiation of ART. Educational status, occupation, advanced clinical stage and OI prophylaxis therapy were predictors ADRs. Continuous counseling for non-educated patients and clients in clinical stage II and above, and patients didn't take OI prophylaxis need to get close follow up to prevent the associated ADRs by the concerned parties.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。